Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer

Maurizio Cosimelli, Raffaello Mancini, Livio Carpanese, Rosa Sciuto, Giuseppe Pizzi, Giada Pattaro, Carlo Ludovico Maini

Research output: Contribution to journalArticle

Abstract

Introduction: Radioembolisation (selective internal radiation therapy; SIRT), as part of a continuous strategy contributed to the improvement in response rates and median survival for unresectable metastatic colorectal cancer. Therefore, the role of SIRT in the different stages of treatment plan was investigated in this review. Areas covered: After a brief description of the principles of SIRT, the review focused on the clinical evidences of published trials on the current experience of radioembolisation and its role in both salvage setting and earlier lines of chemotherapy. Expert opinion: Evidence from Phase I studies and small Phase II/III randomised controlled trials has provided an early signal of the safety and improved overall survival, which can be achieved with radioembolisation and chemotherapy compared with chemotherapy (alone), due to an improved liver control. In the salvage setting, interesting results were observed in term of response, toxicity and median overall survival. Until the results of these early-line randomised trials will be available, radioembolisation could be considered either alone or combined with an appropriate chemotherapy regimen following failure of first- or second-line therapy.

Original languageEnglish
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue numberSUPPL.2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Combined Modality Therapy
Chemotherapy
Liver
Colorectal Neoplasms
Drug Therapy
Salvaging
Radiotherapy
Expert Testimony
Toxicity
Survival Rate
Randomized Controlled Trials
Safety
Therapeutics

Keywords

  • Y
  • colorectal cancer
  • liver
  • metastases
  • radioembolisation
  • selective internal radiotherapy
  • SIRT
  • yttrium-90 resin microspheres

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. / Cosimelli, Maurizio; Mancini, Raffaello; Carpanese, Livio; Sciuto, Rosa; Pizzi, Giuseppe; Pattaro, Giada; Maini, Carlo Ludovico.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. SUPPL.2, 04.2012.

Research output: Contribution to journalArticle

Cosimelli, Maurizio ; Mancini, Raffaello ; Carpanese, Livio ; Sciuto, Rosa ; Pizzi, Giuseppe ; Pattaro, Giada ; Maini, Carlo Ludovico. / Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. SUPPL.2.
@article{8665e41315714134bd74a77b81a1eb49,
title = "Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer",
abstract = "Introduction: Radioembolisation (selective internal radiation therapy; SIRT), as part of a continuous strategy contributed to the improvement in response rates and median survival for unresectable metastatic colorectal cancer. Therefore, the role of SIRT in the different stages of treatment plan was investigated in this review. Areas covered: After a brief description of the principles of SIRT, the review focused on the clinical evidences of published trials on the current experience of radioembolisation and its role in both salvage setting and earlier lines of chemotherapy. Expert opinion: Evidence from Phase I studies and small Phase II/III randomised controlled trials has provided an early signal of the safety and improved overall survival, which can be achieved with radioembolisation and chemotherapy compared with chemotherapy (alone), due to an improved liver control. In the salvage setting, interesting results were observed in term of response, toxicity and median overall survival. Until the results of these early-line randomised trials will be available, radioembolisation could be considered either alone or combined with an appropriate chemotherapy regimen following failure of first- or second-line therapy.",
keywords = "Y, colorectal cancer, liver, metastases, radioembolisation, selective internal radiotherapy, SIRT, yttrium-90 resin microspheres",
author = "Maurizio Cosimelli and Raffaello Mancini and Livio Carpanese and Rosa Sciuto and Giuseppe Pizzi and Giada Pattaro and Maini, {Carlo Ludovico}",
year = "2012",
month = "4",
doi = "10.1517/14728222.2011.647811",
language = "English",
volume = "16",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "SUPPL.2",

}

TY - JOUR

T1 - Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer

AU - Cosimelli, Maurizio

AU - Mancini, Raffaello

AU - Carpanese, Livio

AU - Sciuto, Rosa

AU - Pizzi, Giuseppe

AU - Pattaro, Giada

AU - Maini, Carlo Ludovico

PY - 2012/4

Y1 - 2012/4

N2 - Introduction: Radioembolisation (selective internal radiation therapy; SIRT), as part of a continuous strategy contributed to the improvement in response rates and median survival for unresectable metastatic colorectal cancer. Therefore, the role of SIRT in the different stages of treatment plan was investigated in this review. Areas covered: After a brief description of the principles of SIRT, the review focused on the clinical evidences of published trials on the current experience of radioembolisation and its role in both salvage setting and earlier lines of chemotherapy. Expert opinion: Evidence from Phase I studies and small Phase II/III randomised controlled trials has provided an early signal of the safety and improved overall survival, which can be achieved with radioembolisation and chemotherapy compared with chemotherapy (alone), due to an improved liver control. In the salvage setting, interesting results were observed in term of response, toxicity and median overall survival. Until the results of these early-line randomised trials will be available, radioembolisation could be considered either alone or combined with an appropriate chemotherapy regimen following failure of first- or second-line therapy.

AB - Introduction: Radioembolisation (selective internal radiation therapy; SIRT), as part of a continuous strategy contributed to the improvement in response rates and median survival for unresectable metastatic colorectal cancer. Therefore, the role of SIRT in the different stages of treatment plan was investigated in this review. Areas covered: After a brief description of the principles of SIRT, the review focused on the clinical evidences of published trials on the current experience of radioembolisation and its role in both salvage setting and earlier lines of chemotherapy. Expert opinion: Evidence from Phase I studies and small Phase II/III randomised controlled trials has provided an early signal of the safety and improved overall survival, which can be achieved with radioembolisation and chemotherapy compared with chemotherapy (alone), due to an improved liver control. In the salvage setting, interesting results were observed in term of response, toxicity and median overall survival. Until the results of these early-line randomised trials will be available, radioembolisation could be considered either alone or combined with an appropriate chemotherapy regimen following failure of first- or second-line therapy.

KW - Y

KW - colorectal cancer

KW - liver

KW - metastases

KW - radioembolisation

KW - selective internal radiotherapy

KW - SIRT

KW - yttrium-90 resin microspheres

UR - http://www.scopus.com/inward/record.url?scp=84858964969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858964969&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.647811

DO - 10.1517/14728222.2011.647811

M3 - Article

C2 - 22443155

AN - SCOPUS:84858964969

VL - 16

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - SUPPL.2

ER -